Leering Partners Lifts Disc Medicine, Inc. (IRON) Following EPP Drug NDA Application

Core Insights - Disc Medicine Inc. is recognized as a promising biotech stock by Wall Street analysts, with price target increases from multiple firms following positive developments in its drug pipeline [1][2][3] Group 1: Price Target Increases - Leerink Partners raised the price target for Disc Medicine Inc. to $115 from $110, maintaining an Outperform rating [1][2] - Raymond James also increased its price target to $117 from $108, reiterating a Strong Buy rating [3] Group 2: Drug Development and Clinical Trials - The price target hikes are attributed to the acceptance of the New Drug Application for bitopertin, an oral GlyT-1 inhibitor for erythropoietic protoporphyria (EPP) by the FDA [2] - The company reported topline interim data from the Phase 2 RALLY-MF trial in patients with myelofibrosis anemia, which has bolstered confidence in the drug's prospects [2][3] - Revenue forecasts for the company have been raised significantly to approximately $748 million from $359 million, reflecting optimism about the success of its candidate drug DISC-0974 in myelofibrosis [2] Group 3: Company Overview - Disc Medicine, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for serious hematologic diseases by targeting red blood cell biology, specifically heme production and iron balance [4]